Anticorps Recombinant de lapin anti-KMT2C

KMT2C Recombinant Antibody for IF/ICC, FC (Intra), ELISA

Hôte / Isotype

Lapin / IgG

Réactivité testée

Humain

Applications

IF/ICC, FC (Intra), ELISA

Conjugaison

Non conjugué

CloneNo.

240542A2

N° de cat : 83595-4-RR

Synonymes

MLL3, 240542A2, HALR, Homologous to ALR protein, KIAA1506



Applications testées

Résultats positifs en IF/ICCcellules MCF-7,
Résultats positifs en FC (Intra)cellules U2OS,

Dilution recommandée

ApplicationDilution
Immunofluorescence (IF)/ICCIF/ICC : 1:125-1:500
Flow Cytometry (FC) (INTRA)FC (INTRA) : 0.25 ug per 10^6 cells in a 100 µl suspension
It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
Sample-dependent, check data in validation data gallery

Informations sur le produit

83595-4-RR cible KMT2C dans les applications de IF/ICC, FC (Intra), ELISA et montre une réactivité avec des échantillons Humain

Réactivité Humain
Hôte / Isotype Lapin / IgG
Clonalité Recombinant
Type Anticorps
Immunogène KMT2C Protéine recombinante Ag28875
Nom complet myeloid/lymphoid or mixed-lineage leukemia 3
Masse moléculaire calculée 541 kDa
Numéro d’acquisition GenBankNM_170606
Symbole du gène KMT2C
Identification du gène (NCBI) 58508
Conjugaison Non conjugué
Forme Liquide
Méthode de purification Protein A purfication
Tampon de stockage PBS with 0.02% sodium azide and 50% glycerol
Conditions de stockageStocker à -20°C. Stable pendant un an après l'expédition. L'aliquotage n'est pas nécessaire pour le stockage à -20oC Les 20ul contiennent 0,1% de BSA.

Informations générales

Lysine (K)-specific methyltransferase 2C (KMT2C, also known as MLL3) belongs to the mixed-lineage leukemia (MLL) family of histone methyltransferases which methylate the histone 3 tail at lysine 4 (H3K4) as part of the complex proteins associated with Set 1 (COMPASS) complex. Although originally identified as oncogenic fusions in leukemia, genome-wide mutation studies have revealed frequent, presumably loss-of-function, mutations in various members of the MLL family, including MLL2/KMT2B, MLL3/KMT2C, and MLL4/KMT2D in a variety of malignancies, particularly solid tumors. Mechanistic studies of KMT2C in normal cells have focused primarily on its role in enhancer regulation by deposition of H3K4me1 marks.

Protocole

Product Specific Protocols
IF protocol for KMT2C antibody 83595-4-RRDownload protocol
Standard Protocols
Click here to view our Standard Protocols
{{ptg:RelatedPrimaryAntibodies}}